Abstract
Introduction: Type 2 Diabetes Mellitus (T2DM) has witnessed a rise in its prevalence worldwide and in the Middle East region. The overall burden associated with the disease is well characterized, but little is known about patient satisfaction in the region. The purpose of the study is to evaluate the quality of life (QoL) and treatment satisfaction of patients T2DM. Methods: The SIMPLIFY study was an observational, cross-sectional, multicenter, regional study that used patient-reported outcomes of T2DM patients in Jordan and Lebanon. Results: Patients were more satisfied when they were treated exclusively with oral medications, mainly metformin alone or combined with either sulfonylurea or dipeptidyl peptidase-4 inhibitor. Targets for glycated hemoglobin (HbA1c) values were better reached in patients treated with oral medications. Occurrence of comorbidities did not seem to be affected by oral or injectable medications or to affect patients’ satisfaction. Data highlighted a suboptimal screening for albuminuria and showed that most patients were overweight or obese and around 30% suffered from hypoglycemia episodes. Conclusion: Data shed the light on the management of T2DM in Jordan and Lebanon and suggested the need for a more comprehensive approach to T2DM management and selection of medications that would support weight control and a lower hypoglycemia incidence.
Highlights
Type 2 Diabetes Mellitus (T2DM) has witnessed a rise in its prevalence worldwide and in the Middle East region
Data highlighted a suboptimal screening for albuminuria and showed that most patients were overweight or obese and around 30% suffered from hypoglycemia episodes
An increase in the prevalence of diabetes in the Levant region was observed in the last two decades with a prevalence reaching around 12% in Jordan and 8% in Lebanon [2] [3], and a major increase is yet predicted by the World Health Organization (WHO) for the year 2030 in both countries [4]
Summary
Type 2 Diabetes Mellitus (T2DM) has witnessed a rise in its prevalence worldwide and in the Middle East region. Global data show an endemic rise in the prevalence of diabetes, mainly due to T2DM, with an estimated increase between 2017 and 2045 of 48% worldwide and of 112% in the Middle East and North Africa region [2]. Current diabetes care employs more patient-active strategies with individualized treatment goals and plans [5] This is of prime importance since the ability of a patient to carry out their management plan is as vital as the plan itself [5], and engaging patients in healthcare decisions may enhance adherence to therapy [6] and Quality of Life (QoL) [5]. With the use of more complex medication regimen, the risk of adverse events, drug interactions, increased cost and lower compliance will rise [6]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
